SCHEMBL4291285

SCHEMBL4291285

COc1ccccc1NS(=O)(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.68
PKM P14618 1/20 0.62
KMT2A Q03164 2/20 0.60
SLC10A6 Q3KNW5 1/20 0.58
NFKBIA P25963 2/20 0.56
RELA Q04206 2/20 0.56
LMNA P02545 2/20 0.56
TDP1 Q9NUW8 3/20 0.55
MEN1 O00255 1/20 0.55
MDM4 O15151 1/20 0.55
OPRK1 P41145 1/20 0.55
MDM2 Q00987 1/20 0.55
SLC40A1 Q9NP59 1/20 0.55
NPC1 O15118 1/20 0.54
TSHR P16473 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
MMP1 P03956 1/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15658709 0.86 GUSB (0.67) ALDH1A1KMT2ALMNATDP1MEN1
SCHEMBL17805683 0.81 PKM (0.71) ALDH1A1PKMKMT2ASLC10A6NFKBIA
SCHEMBL16680267 0.80 SMN1; SMN2 (0.67) ALDH1A1PKMKMT2ALMNAMEN1
SCHEMBL6343982 0.80 SMN1; SMN2 (0.60) ALDH1A1PKMKMT2ASLC10A6LMNA
SCHEMBL13265815 0.80 AMY1A (0.54) ALDH1A1KMT2ALMNAMEN1NPC1
SCHEMBL7451030 0.80 PKM (0.64) PKMKMT2ASLC10A6NFKBIARELA
SCHEMBL8276485 0.80 KMT2A (0.62) ALDH1A1PKMKMT2ALMNATDP1
SCHEMBL2239360 0.79 HPGD (0.74) ALDH1A1PKMKMT2ALMNATDP1
SCHEMBL16679842 0.79 GAA (0.55) ALDH1A1PKMLMNATDP1CA1
SCHEMBL3780817 0.78 PKM (0.63) PKMKMT2ASLC10A6NFKBIARELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655299-A1 NEW COMPOUNDS FOR TREATING STAPHYLOCOCCUS INFECTIONS Ab2 Therapeutics, S. L. (ES) 2025-12-03 EP disclosed
WO-2024156895-A1 NEW COMPOUNDS FOR TREATING STAPHYLOCOCCUS INFECTIONS ABAC Therapeutics, S.L. (ES) 2024-08-02 WO disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT ALDH1A1 388/4885PKM 847/4885KMT2A 1049/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT ALDH1A1 388/4885PKM 847/4885KMT2A 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.